The Hematology/Oncology Pharmacy Association (HOPA) has joined forces with several fellow medical associations and organizations to speak out against the immense proposed cuts to the future of cancer care, medical research, and health care in the United States.

HOPA recently added its voice to multiple letters advocating for Congress to reject the drastic, wide-ranging health care cuts found in the proposed Fiscal Year 2026 budget. These cuts - which include up to $700 billion from Medicaid, $18 billion from the National Institutes of Health, the elimination of the Grad PLUS loan program, and more - will harm the future of our nation's pharmacist workforce, put people's health care at risk, and set back our country's progress in the fight against cancer.

To help combat these proposed cuts, HOPA has signed the following advocacy letters and statements:

To read these statements in full - as well as other recent advocacy letters backed by HOPA - visit the sign-on letters page in HOPA's Press Room.

HOPA is proud to join these fellow groups in speaking out against these substantial, harmful cuts. Our voices are only stronger together. And to add your individual voice to these calls to reject the current budget cuts, visit HOPA's Legislative Action Center, which features easy-to-use tools for sharing your story, perspective, and advocacy with elected officials.

Together we can save cancer care - and lives.

U.S. Capitol Building
Advocacy

What HOPA Members Should Know About the End of the 2025 U.S. Government Shutdown

On Wednesday, November 12, Congress passed a continuing resolution to re-open the government after a record 43-day shutdown. Here's what HOPA members should know about the bill and what's happening next.

Map of the sub-Saharan African region
Advocacy

HOPA Endorses ISOPP & UICC Statement on Ensuring International Cancer Drug Quality and Equity

ISOPP and UICC recently released a statement calling for quality and equity of cancer treatments in sub-Saharan Africa. HOPA has joined with oncology and pharmacy organizations worldwide to endorse their statement.

Images of DNA strands for DPYD genetic testing
Advocacy

HOPA Supports FDA Box Label Changes for DPYD Testing

We support the FDA's updated guidance concerning DPD deficiency and fluoropyrimidine drugs, and urge healthcare providers to integrate DPYD genetic testing into clinical practice.